Showing papers by "Anne Chao published in 2018"
TL;DR: This work presents a unifying framework for the measurement of biodiversity across hierarchical levels of organization based on a Hill number of order q = 1, which weights all elements in proportion to their frequency and leads to diversity measures based on Shannon's entropy.
Abstract: This work was assisted through participation in “Next Generation Genetic Monitoring” Investigative Workshop at the National Institute for Mathematical and Biological Synthesis, sponsored by the National Science Foundation through NSF Award #DBI-1300426, with additional support from The University of Tennessee, Knoxville. Hawaiian fish community data were provided by the NOAA Pacific Islands Fisheries Science Center's Coral Reef Ecosystem Division (CRED) with funding from NOAA Coral Reef Conservation Program. O.E.G. was supported by the Marine Alliance for Science and Technology for Scotland (MASTS). A. C. and C. H. C. were supported by the Ministry of Science and Technology, Taiwan. P.P.-N. was supported by a Canada Research Chair in Spatial Modelling and Biodiversity. K.A.S. was supported by National Science Foundation (BioOCE Award Number 1260169) and the National Center for Ecological Analysis and Synthesis. All data used in this manuscript are available in DRYAD (https://doi.org/dx.doi.org/10.5061/dryad.qm288) and BCO-DMO (http://www.bco-dmo.org/project/552879).
50 citations
TL;DR: Early microcirculatory parameters could be used to predict the survival of cardiogenic shock patients with VA-ECMO support, and these values exhibited less favorable survival compared with the other two subgroups.
Abstract: Microcirculatory dysfunction develops in both septic and cardiogenic shock patients, and it is associated with poor prognosis in patients with septic shock. Information on the association between microcirculatory dysfunction and prognosis in cardiogenic shock patients with venoarterial extracorporeal membrane oxygenation (VA-ECMO) support is limited. Sublingual microcirculation images were recorded using an incident dark-field video microscope at the following time points: within 12 h (T1), 24 h (T2), 48 h (T3), 72 h (T4), and 96 h (T5) after VA-ECMO placement. If a patient could be weaned off VA-ECMO, sublingual microcirculation images were recorded before and after VA-ECMO removal. Microcirculatory parameters were compared between 28-day nonsurvivors and survivors with VA-ECMO support. In addition, the microcirculation and clinical parameters were assessed as prognostic tests of 28-day mortality, and patients were divided into three subgroups according to microcirculation parameters for survival analysis. Forty-eight patients were enrolled in this study. At T1, the observed heart rate, mean arterial pressure, inotropic score and lactate level of 28-day nonsurvivors and survivors did not differ significantly, but the perfused small vessel density (PSVD) and proportion of perfused vessels (PPV) were lower in the 28-day nonsurvivors than in the survivors. The PSVD and PPV were slightly superior to lactate levels in predicting 28-day mortality (area under curve of 0.68, 0.70, and 0.62, respectively). The subgroup with the lowest PSVD (< 15 mm/mm2) and PPV (< 64%) values exhibited less favorable survival compared with the other two subgroups. Early microcirculatory parameters could be used to predict the survival of cardiogenic shock patients with VA-ECMO support. ClinicalTrials.gov, NCT02393274
. Registered on 19 March 2015.
46 citations
TL;DR: Cardiac index did not differ significantly between the dexmedetomidine and propofol groups in surgical ICU patients in surgical intensive care unit (ICU) patients after major abdominal surgery.
15 citations
TL;DR: Symptomatic CCHs respond generally well to PDT, and patients with younger age, pretreatment BCVA≥ 20/200, and thinner foveal edema are most likely to benefit from this approach.
Abstract: Background To investigate the treatment outcomes and predictors of response to photodynamic therapy (PDT) in patients with symptomatic circumscribed hemangioma (CCH). Methods This retrospective case series examined 20 patients with symptomatic CCH (10 submacular CCHs and10 juxtapapillary CCHs) who underwent standard PDT (wavelength: 662 nm; light dose: 50J/cm2; exposure time: 83 sec) with verteporfin (6mg/m2), either as monotherapy (n = 9) or in association with other treatments (n = 11), of which 7 received intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF). A post-PDT improvement of at least two lines in best-corrected visual acuity (BCVA) was the primary outcome measure. Predictors of response were investigated with binary logistic regression analysis. Results Seventeen (85%) patients received one PDT session, and three patients (15%) underwent PDT at least twice. Ten patients (50%) achieved the primary outcome of a post-PDT BCVA improvement of at least two lines. Macular atrophy and recalcitrant cystoid macular edema in 2 patients. Binary logistic regression analysis revealed that younger age (< 50 years) (P = 0.033), pre-PDT BCVA of ≧20/200 (P = 0.013), exudative retinal detachment resolved within one month after PDT (P = 0.007), and a thinner post-PDT tumor thickness (P = 0.015) were associated with the achievement of a post-PDT BCVA improvement. Additional treatments to PDT including IVI anti-VEGF did not appear to improve visual and anatomical outcomes. Conclusions Symptomatic CCHs respond generally well to PDT. Patients with younger age (< 50 years), pretreatment BCVA≥ 20/200, and thinner foveal edema are most likely to benefit from this approach.
11 citations
TL;DR: PMX‐HP improved survival in septic shock patients with intra‐abdominal infection and was associated with lower 28‐day mortality and greater improvement in inotropic and APACHE II scores.
9 citations
TL;DR: Age and sex were correlated with microcirculatory parameters of the healthy volunteers and patients with sepsis, and microcirculation dysfunction was more severe in the 28-day nonsurvivor group than in the28-day survivor group.
7 citations
3 citations
TL;DR: PMX‐HP improved survival in septic shock patients with intra‐abdominal infection and was associated with lower 28‐day mortality and greater improvement in inotropic and APACHE II scores.